Malignant pleural mesothelioma
Conditions
Interventions
None listed
Sponsors
Hyogo college of medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1 Patients who have been confirmed as MPM by histology or cytology. (Epithelial type, sarcoma type and bilayer type are not limited) 2 MPM patients who received previous platinum agent and pemetrexede combination therapy and were judged as progressive disease. 3 Patients with at least one measurable lesion as defined by mRECIST using CT or MRI 4 Patients who can receive nivolumab therapy 5 Patients who received full explanation from investigators or research sharing doctors regarding contents of this research using agreement document and explanation document and who consented to participate in this research by the person himself or herself
Exclusion criteria
Exclusion criteria: 1 Patients receiving pervious systemic chemotherapies (two or more regimens), including platinum agent and pemetrexede combination therapy. 2 Patients with ECOG PS 2 or more 3 Patients receiving steriod therapy (10mg per day or more) 4 Patients receiving antibiotics between 4 weeks before and after the nivolumab therapy 5 Patients who are deemed inappropriate as study participants by investigators or medical doctors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression Free Survival Overall survival | — |
Countries
Japan
Contacts
Public ContactSeiji Matsumoto
Hyogo college of medicine Department of Thoracic Surgery
Outcome results
None listed